Drug development company has new CEO
MANCHESTER-based drug discovery and development company C4X has appointed Dr Clive Dix as its new chief executive with immediate effect.
Dix joined listed C4X Discovery Holdings in October 2014 as non-executive chairman and became chairman in November 2015.
Non-executive director Sam Williams will become interim chairman while a search for a new chairman is carried out.
Dix said: “Having seen from an executive position the potential of the platform to generate entirely new compounds against high-value therapeutic targets more rapidly and efficiently than any technology I’ve come across before and having witnessed the interest we’re receiving in C4X Discovery, I am delighted to take the helm on a full-time basis.
“I have never been more excited by a company than this one.”
Dix is widely recognised as one of the leading figures in the UK biotechnology sector, combining track records as a serially successful entrepreneur and an experienced pharmaceutical R&D executive.
Most recently, Dix was CEO of Convergence Pharmaceuticals, which was sold to Biogen in January 2015 for $675m. Prior to that, he enjoyed successful exits with PowderMed, Auralis and PowderJect Pharmaceuticals plc, where he held the roles of CEO, chairman and head of R&D, respectively.
Before his move into biotechnology, Dix was UK research director for GlaxoWellcome. He currently serves as chairman of Touchlight Genetics and Centauri Therapeutics, and was chairman of the UK BioIndustry Association (BIA) from 2008-2010.
